Pancreatic Cancer Surgery & Whipple Procedure Surgeon in the San Francisco Bay Area

Pancreatic Cancer Surgery and Multidisciplinary Treatment Planning

Pancreatic cancer surgery is a highly specialized field requiring careful integration of tumor biology, high-resolution imaging, pancreatic ductal anatomy, and multidisciplinary cancer care.

Dr. Geoffrey W. Krampitz is a fellowship-trained pancreatic cancer surgeon and hepatopancreatobiliary (HPB) surgical oncologist serving patients throughout the San Francisco Bay Area. His clinical practice focuses on pancreatic cancer surgery and complex hepatopancreatobiliary (HPB) operations, including the Whipple procedure, distal pancreatectomy, and selective vascular reconstruction when oncologically indicated. He also evaluates and surgically manages other complex pancreatic tumors, including pancreatic cystic neoplasms and pancreatic neuroendocrine tumors.

This section reflects a focused HPB surgical oncology practice dedicated to complex pancreatic conditions, with treatment strategies guided by careful interpretation of imaging, tumor biology, and multidisciplinary treatment planning.

Early Surgical Evaluation in Pancreatic Cancer

Early surgical evaluation is an important component of modern pancreatic cancer care. Consultation with a pancreatic cancer surgeon allows imaging findings, tumor biology, and systemic therapy strategy to be integrated into a coordinated treatment plan.

Patients may benefit from surgical evaluation when the following are identified:

  • Newly diagnosed pancreatic cancer

  • Pancreatic masses suspicious for malignancy

  • Borderline resectable tumors with vascular involvement

  • Pancreatic tumors requiring multidisciplinary treatment sequencing

Early consultation allows coordinated planning of:

  • high-quality staging imaging

  • systemic therapy sequencing

  • biliary decompression when necessary

  • operative strategy and timing

Because pancreatic cancer treatment increasingly involves multidisciplinary and systemic-first approaches, early involvement of surgical oncology helps ensure that operative decisions are aligned with tumor biology and overall treatment strategy.

Pancreatic Cancer Surgery and Tumor Biology

Pancreatic ductal adenocarcinoma (PDAC) is a biologically aggressive malignancy in which operative decisions must be guided by both anatomic resectability and tumor biology.

Surgery is not an isolated intervention. In contemporary pancreatic cancer care, it represents one component of a carefully sequenced, multidisciplinary treatment strategy designed to address both local disease and early systemic risk.

As a fellowship-trained robotic surgical oncologist and hepatopancreatobiliary (HPB) surgeon with advanced training at Stanford University and MD Anderson Cancer Center, Dr. Geoffrey W. Krampitz specializes in complex pancreatic cancer surgery in the San Francisco Bay Area, including:

  • Pancreaticoduodenectomy (Whipple procedure)

  • Distal pancreatectomy

  • Selective venous resection and reconstruction when oncologically indicated

Pancreatic cancer biology and mechanisms of tumor progression have been a sustained area of academic focus throughout Dr. Krampitz’s surgical and research training. This translational perspective informs operative decision-making, particularly in the integration of systemic therapy response, molecular profiling, and resectability assessment.

Operative platform selection — open or robotic — is determined by oncologic priorities, vascular involvement, tumor biology, and patient safety.

For biomarker-driven strategy, see Molecular Oncology & Surgical Strategy.

Understanding Pancreatic Ductal Adenocarcinoma (PDAC)

Most pancreatic cancers arise from the exocrine ductal epithelium and are classified as pancreatic ductal adenocarcinoma (PDAC).

This disease is biologically distinct from pancreatic neuroendocrine tumors, which follow a separate natural history and require different management strategies.

Because the pancreas lies deep within the retroperitoneum, early symptoms are often subtle and nonspecific.

Common Presenting Symptoms

  • Jaundice

  • Epigastric or back pain

  • Unintended weight loss

  • Fatigue

  • Changes in appetite or digestion

Evaluation is recommended when symptoms or imaging findings raise concern.

Role of the Pancreatic Cancer Surgeon in Treatment Planning

Management of pancreatic cancer requires careful integration of surgical oncology, medical oncology, gastroenterology, radiology, and pathology. Within this multidisciplinary framework, the pancreatic cancer surgeon plays a central role in evaluating anatomic resectability, interpreting imaging findings, and determining whether surgery should occur immediately or after systemic therapy.

Pancreatic cancer surgery includes several complex procedures, most commonly:

  • Pancreaticoduodenectomy (Whipple procedure) for tumors of the pancreatic head

  • Distal pancreatectomy for tumors of the pancreatic body and tail

  • Selective venous resection and reconstruction when required to achieve margin-negative resection

Because pancreatic cancer frequently involves major vascular structures such as the superior mesenteric vein (SMV) and portal vein, operative planning must be integrated with systemic therapy strategy and careful multidisciplinary review.

Evaluation by a surgeon experienced in pancreatic cancer surgery and the Whipple procedure, as well as hepatopancreatobiliary (HPB) oncology, helps determine the safest and most effective treatment sequence.

Diagnosis and Staging: Defining Operative Strategy

Accurate staging determines not only whether a tumor is technically removable — but whether surgery is oncologically appropriate at that point in the disease course.

Imaging Evaluation of Pancreatic Cancer

High-Quality Cross-Sectional Imaging

  • Pancreas-protocol CT scan

  • CT scan of the chest

  • MRI in selected cases

Particular attention is directed to tumor interface with the:

  • Superior mesenteric artery (SMA)

  • Superior mesenteric vein (SMV)

  • Portal vein

Vascular involvement — rather than tumor size alone — frequently determines treatment sequencing.

Endoscopic Evaluation

  • Endoscopic ultrasound (EUS) with biopsy

  • ERCP for biliary decompression when clinically necessary

Laboratory Assessment

  • CA 19-9

  • CEA

  • IgG4 when autoimmune pancreatitis is under consideration

Resectability Classification and Treatment Sequencing

Pancreatic cancer is categorized as:

  • Resectable – No major arterial involvement

  • Borderline resectable – Limited arterial abutment or reconstructable venous involvement

  • Locally advanced – Significant arterial encasement without distant metastasis

  • Metastatic – Distant organ spread

Modern pancreatic cancer management increasingly emphasizes systemic-first strategies, even in anatomically resectable disease, to:

  • Address micrometastatic disease early

  • Assess biologic response

  • Improve margin-negative (R0) resection rates

  • Reduce early systemic recurrence

The objective is not simply tumor removal — but durable disease control through disciplined sequencing.

Treatment plans are determined through structured multidisciplinary evaluation integrating surgical oncology, medical oncology, gastroenterology, radiology, and pathology.

Borderline Resectable Pancreatic Cancer

Borderline resectable pancreatic cancer refers to tumors in which immediate surgery may not provide the best oncologic outcome, but carefully sequenced treatment may allow eventual surgical resection with curative intent.

These tumors frequently demonstrate limited involvement of adjacent vascular structures, raising concern that immediate surgery could result in positive margins or complex vascular reconstruction.

For this reason, many patients with borderline resectable pancreatic cancer benefit from systemic therapy prior to surgery, allowing assessment of tumor biology and potential downstaging before operative intervention.

Several classification systems have been proposed to define borderline resectable pancreatic cancer. A widely used framework developed at MD Anderson Cancer Center categorizes patients based on anatomic, biologic, and clinical risk factors.

Type A: Anatomic Borderline Resectable Disease

Type A borderline resectable pancreatic cancer refers to tumors with limited involvement of adjacent vascular structures that may require vascular resection and reconstruction during surgery.

Examples may include:

  • Tumor abutment of the superior mesenteric vein (SMV) or portal vein

  • Short-segment venous narrowing that remains technically reconstructable

  • Limited arterial abutment without encasement

In these situations, neoadjuvant systemic therapy may improve the likelihood of achieving a margin-negative (R0) resection.

Type B: Borderline Resectable Disease Based on Tumor Biology

Type B borderline resectable disease reflects concerning biologic features despite technically resectable anatomy on imaging.

Examples may include:

  • Markedly elevated tumor markers such as CA 19-9

  • Suspicious regional lymph nodes

  • Imaging findings suggesting aggressive tumor biology

In these cases, systemic therapy prior to surgery allows assessment of treatment responsiveness and disease behavior.

Type C: Borderline Resectable Disease Based on Patient Condition

Type C borderline resectable pancreatic cancer refers to situations in which patient factors limit the safety or appropriateness of immediate surgery.

Examples may include:

  • Marginal physiologic reserve

  • Significant medical comorbidities

  • Performance status concerns

In these patients, systemic therapy and supportive care may allow clinical optimization prior to surgery.

Treatment Strategy

For many patients with borderline resectable pancreatic cancer, treatment begins with systemic therapy, followed by reassessment with high-quality imaging and multidisciplinary review.

Patients demonstrating stable disease or treatment response may then proceed to pancreatic resection, which may involve procedures such as the Whipple procedure (pancreaticoduodenectomy) or distal pancreatectomy, sometimes combined with venous resection and reconstruction when necessary to achieve margin-negative resection.

Careful sequencing of systemic therapy, imaging reassessment, and operative planning helps optimize both oncologic outcomes and surgical safety. In many of these cases, the critical technical question is whether venous involvement remains reconstructable while maintaining oncologic integrity.

Vascular Involvement in Pancreatic Cancer

Pancreatic tumors often arise in close proximity to major blood vessels, including the superior mesenteric vein, portal vein, and superior mesenteric artery. Careful imaging evaluation is essential to determine the relationship between the tumor and these structures.

Venous reconstruction most commonly involves the SMV–portal vein confluence, where pancreatic tumors frequently abut or partially involve the vessel wall.

In selected patients, limited involvement of the portal vein or superior mesenteric vein may be addressed with venous resection and reconstruction during pancreatic cancer surgery in order to achieve a margin-negative resection.

Reconstruction techniques may include:

  • primary venous repair

  • patch venoplasty

  • segmental venous resection with interposition graft

Patch reconstruction may utilize biologic materials such as bovine pericardial patch grafts, while interposition grafts may involve autologous vein grafts or cryopreserved venous grafts when necessary.

The decision to proceed with vascular resection depends on tumor biology, response to systemic therapy, and multidisciplinary treatment planning.

Surgical management may involve procedures such as the Whipple procedure or distal pancreatectomy depending on tumor location.

Surgical Techniques in Pancreatic Cancer

Pancreatic resection is undertaken only when strict oncologic standards can be achieved, including negative margins and appropriate lymph node assessment.

Whipple Procedure (Pancreaticoduodenectomy)

The Whipple procedure is performed for tumors of the pancreatic head and involves removal of:

  • Pancreatic head

  • Duodenum

  • Distal bile duct

  • Gallbladder

  • Regional lymph nodes

Meticulous dissection is performed along the SMA, SMV, and portal vein.

In selected patients, limited venous resection and reconstruction may be required to achieve margin-negative resection while preserving oncologic integrity.

Distal Pancreatectomy

For tumors of the pancreatic body or tail, distal pancreatectomy includes removal of:

  • Distal pancreas

  • Often the spleen

  • Regional lymph nodes

Spleen-preserving approaches may be considered for selected benign or low-grade lesions.

For cystic precursor lesions such as IPMN or MCN, see Pancreatic Cysts.

Robotic Pancreatic Surgery and Operative Platform Selection

When anatomically appropriate, pancreatic resection may be performed using advanced robotic-assisted techniques.

Robotic platforms provide:

  • Enhanced three-dimensional visualization

  • Wristed instrument articulation

  • Refined retroperitoneal and vascular dissection

These advantages may support precision in carefully selected patients.

Technology does not replace oncologic judgment.
Operative platform selection is determined by disease characteristics, vascular anatomy, prior therapy, and overall patient condition.

More information about minimally invasive approaches is available in the Robotic Pancreatic Surgery section.

Programmatic Expertise and Perioperative Management

Pancreatic surgery requires specialized perioperative infrastructure and experienced multidisciplinary support.

Potential complications include:

  • Pancreatic fistula

  • Bleeding

  • Delayed gastric emptying

  • Endocrine dysfunction (including diabetes)

  • Exocrine pancreatic insufficiency

Enhanced recovery pathways, structured complication management protocols, and coordinated postoperative surveillance are central components of care.

Why Experience Matters in Pancreatic Surgery

Outcomes are closely associated with surgeon expertise, multidisciplinary coordination, vascular reconstruction experience, and integration of systemic therapy strategy — factors that influence margin status, complication management, and long-term survival.

Care is delivered within an experienced HPB-focused program committed to oncologic rigor and continuous quality review.

Genetic and Molecular Testing in Pancreatic Cancer

Current national guidelines recommend:

  • Germline genetic testing for all patients diagnosed with pancreatic cancer

  • Tumor molecular profiling when feasible

Identification of DNA damage repair pathway alterations (such as BRCA1/2 or PALB2) may influence systemic therapy selection, clinical trial eligibility, and screening recommendations for family members.

Emerging data suggest that pancreatic ductal adenocarcinoma exhibits biologic heterogeneity both within the primary tumor and between primary and metastatic sites. Differences in molecular profile, stromal composition, and treatment responsiveness may influence recurrence patterns and systemic therapy sensitivity.

Ongoing translational research continues to refine risk stratification beyond anatomic staging alone.

For additional discussion, see Molecular Oncology & Surgical Strategy.

Multidisciplinary Pancreatic Cancer Care

Optimal outcomes require coordinated collaboration among:

  • Surgical oncology

  • Medical oncology

  • Gastroenterology

  • Radiology and pathology

  • Nutrition and supportive care specialists

Treatment sequencing aligns systemic therapy, operative timing, and surveillance with oncologic priorities and tumor biology.

Conclusion: A Biology-Integrated Surgical Strategy

Pancreatic cancer management demands disciplined integration of:

  • Tumor biology

  • Systemic therapy strategy

  • Vascular expertise

  • Operative precision

  • Longitudinal surveillance

Advances in imaging, systemic therapy, molecular characterization, and selective minimally invasive techniques have improved outcomes when care is delivered within experienced, high-acuity pancreatic programs committed to biologic interpretation as well as technical precision.

Pancreatic Cancer Surgical Consultation in the San Francisco Bay Area

Dr. Geoffrey W. Krampitz provides pancreatic cancer surgical consultation for patients throughout the San Francisco Bay Area, including San Mateo County, Silicon Valley, and the broader Northern California region. Patients are frequently referred for evaluation of newly diagnosed pancreatic cancer, borderline resectable tumors, pancreatic cystic neoplasms, and complex pancreatic disease requiring multidisciplinary assessment.

Frequently Asked Questions About Pancreatic Cancer Surgery

Who should perform pancreatic cancer surgery?
Pancreatic surgery is technically demanding and outcomes are closely associated with surgeon experience, multidisciplinary coordination, and institutional infrastructure. Evaluation by a fellowship-trained hepatopancreatobiliary or surgical oncology specialist is recommended.

What is the Whipple procedure?
The Whipple procedure (pancreaticoduodenectomy) is the most common operation performed for pancreatic cancer arising in the head of the pancreas. The operation involves removal of the pancreatic head, duodenum, bile duct, and regional lymph nodes, followed by reconstruction of the digestive tract.

Is pancreatic cancer always treated with surgery first?
Not always. Many patients benefit from systemic therapy before surgery. Treatment sequencing depends on tumor biology, vascular involvement, and overall health status.

Consultation and Referral

For Patients:
Individuals seeking evaluation for pancreatic cancer — including new diagnoses or second opinions — may Request a Consultation to discuss individualized treatment strategy within a coordinated multidisciplinary framework.

For Referring Physicians:
Physicians wishing to refer a patient or discuss complex pancreatic cancer management may visit For Physicians for direct referral pathways and coordinated case review.